Moximed’s MISHA Knee System Receives US FDA’s Market Authorization for Knee Osteoarthritis
Shots:
- The US FDA has granted marketing authorization for the MISHA Knee System designed to relieve pain and improves function in people ineligible for, or unwilling to undergo joint replacement in knee osteoarthritis patients
- In the recent Calypso study, the MISHA knee system met its 1EPs and was found to be superior to high tibial osteotomy (HTO) at 2yrs. & showed an 85.6% composite success rate over (65.5%) in HTO with improvement in pain and function after the procedure. The results were presented at the 12th Orthopaedic Summit (OSET) in Boston
- The MISHA Knee System acts as an implantable shock absorber (ISA), reducing peak forces on the knee by over 30% with every step
Ref: BusinessWire | Image: Moximed
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
